Research ExplorerPublicationsMortality According to Treatment in Metastatic Collecting Du...

Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma

Standard

Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma. / Panunzio, Andrea; Sorce, Gabriele; Tappero, Stefano; Hohenhorst, Lukas; Cano Garcia, Cristina; Piccinelli, Mattia; Tian, Zhe; Tafuri, Alessandro; De Cobelli, Ottavio; Chun, Felix K H; Tilki, Derya; Terrone, Carlo; Briganti, Alberto; Kapoor, Anil; Saad, Fred; Shariat, Shahrokh F; Cerruto, Maria Angela; Antonelli, Alessandro; Karakiewicz, Pierre I.

In: CLIN GENITOURIN CANC, Vol. 21, No. 2, 04.2023, p. 295-300.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Panunzio, A, Sorce, G, Tappero, S, Hohenhorst, L, Cano Garcia, C, Piccinelli, M, Tian, Z, Tafuri, A, De Cobelli, O, Chun, FKH, Tilki, D, Terrone, C, Briganti, A, Kapoor, A, Saad, F, Shariat, SF, Cerruto, MA, Antonelli, A & Karakiewicz, PI 2023, 'Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma', CLIN GENITOURIN CANC, vol. 21, no. 2, pp. 295-300. https://doi.org/10.1016/j.clgc.2022.08.010

APA

Panunzio, A., Sorce, G., Tappero, S., Hohenhorst, L., Cano Garcia, C., Piccinelli, M., Tian, Z., Tafuri, A., De Cobelli, O., Chun, F. K. H., Tilki, D., Terrone, C., Briganti, A., Kapoor, A., Saad, F., Shariat, S. F., Cerruto, M. A., Antonelli, A., & Karakiewicz, P. I. (2023). Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma. CLIN GENITOURIN CANC, 21(2), 295-300. https://doi.org/10.1016/j.clgc.2022.08.010

Vancouver

Panunzio A, Sorce G, Tappero S, Hohenhorst L, Cano Garcia C, Piccinelli M et al. Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma. CLIN GENITOURIN CANC. 2023 Apr;21(2):295-300. https://doi.org/10.1016/j.clgc.2022.08.010

Bibtex

@article{d60098e47143433cb1b8e4947f976f3d,
title = "Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma",
abstract = "INTRODUCTION: Controlled contemporary analyses of mortality in metastatic collecting duct renal cell carcinoma (mcdRCC) are unavailable. We addressed this knowledge gap and tested rates of treatment and associated mortality in patients with mcdRCC.PATIENTS AND METHODS: Within Surveillance, Epidemiology, and End Results database (2004-2018), we identified 155 mcdRCC patients. Kaplan-Meier plots and Cox proportional hazards regression models tested the effect of treatment (cytoreductive nephrectomy [CN] alone vs. systemic therapy [ST] alone vs. combination of both CN + ST) on overall mortality (OM).RESULTS: In the overall cohort (n = 155), 57 patients (37%) were treated with combination of both CN + ST, 46 (30%) underwent CN alone, 28 (18%) received ST alone, and 24 (15%) had none/unknown treatment. According to age categories (≤ 59 vs. 60-69 vs. ≥ 70 years), rates of combination of both CN + ST were 45% vs. 45% vs. 14%, respectively. CN alone was the most frequent type of treatment in patients aged ≥ 70 (50%). Median overall survival was 4.0 months for CN alone vs. 5.5 months for ST alone vs. 9.0 months for combination of both CN+ST. In multivariable Cox regression models, where CN alone was the referent, the use of ST alone and combination of both CN + ST were respectively associated with a HR of 0.74 (P = .3) and 0.43 (P < .001), after adjustment for all covariates.CONCLUSIONS: In mcdRCC patients, concomitant use of CN and ST results in lowest mortality, followed by ST alone, and CN alone. In consequence combination of both CN + ST should be recommended whenever applicable.",
author = "Andrea Panunzio and Gabriele Sorce and Stefano Tappero and Lukas Hohenhorst and {Cano Garcia}, Cristina and Mattia Piccinelli and Zhe Tian and Alessandro Tafuri and {De Cobelli}, Ottavio and Chun, {Felix K H} and Derya Tilki and Carlo Terrone and Alberto Briganti and Anil Kapoor and Fred Saad and Shariat, {Shahrokh F} and Cerruto, {Maria Angela} and Alessandro Antonelli and Karakiewicz, {Pierre I}",
note = "Copyright {\textcopyright} 2022 Elsevier Inc. All rights reserved.",
year = "2023",
month = apr,
doi = "10.1016/j.clgc.2022.08.010",
language = "English",
volume = "21",
pages = "295--300",
journal = "CLIN GENITOURIN CANC",
issn = "1558-7673",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma

AU - Panunzio, Andrea

AU - Sorce, Gabriele

AU - Tappero, Stefano

AU - Hohenhorst, Lukas

AU - Cano Garcia, Cristina

AU - Piccinelli, Mattia

AU - Tian, Zhe

AU - Tafuri, Alessandro

AU - De Cobelli, Ottavio

AU - Chun, Felix K H

AU - Tilki, Derya

AU - Terrone, Carlo

AU - Briganti, Alberto

AU - Kapoor, Anil

AU - Saad, Fred

AU - Shariat, Shahrokh F

AU - Cerruto, Maria Angela

AU - Antonelli, Alessandro

AU - Karakiewicz, Pierre I

N1 - Copyright © 2022 Elsevier Inc. All rights reserved.

PY - 2023/4

Y1 - 2023/4

N2 - INTRODUCTION: Controlled contemporary analyses of mortality in metastatic collecting duct renal cell carcinoma (mcdRCC) are unavailable. We addressed this knowledge gap and tested rates of treatment and associated mortality in patients with mcdRCC.PATIENTS AND METHODS: Within Surveillance, Epidemiology, and End Results database (2004-2018), we identified 155 mcdRCC patients. Kaplan-Meier plots and Cox proportional hazards regression models tested the effect of treatment (cytoreductive nephrectomy [CN] alone vs. systemic therapy [ST] alone vs. combination of both CN + ST) on overall mortality (OM).RESULTS: In the overall cohort (n = 155), 57 patients (37%) were treated with combination of both CN + ST, 46 (30%) underwent CN alone, 28 (18%) received ST alone, and 24 (15%) had none/unknown treatment. According to age categories (≤ 59 vs. 60-69 vs. ≥ 70 years), rates of combination of both CN + ST were 45% vs. 45% vs. 14%, respectively. CN alone was the most frequent type of treatment in patients aged ≥ 70 (50%). Median overall survival was 4.0 months for CN alone vs. 5.5 months for ST alone vs. 9.0 months for combination of both CN+ST. In multivariable Cox regression models, where CN alone was the referent, the use of ST alone and combination of both CN + ST were respectively associated with a HR of 0.74 (P = .3) and 0.43 (P < .001), after adjustment for all covariates.CONCLUSIONS: In mcdRCC patients, concomitant use of CN and ST results in lowest mortality, followed by ST alone, and CN alone. In consequence combination of both CN + ST should be recommended whenever applicable.

AB - INTRODUCTION: Controlled contemporary analyses of mortality in metastatic collecting duct renal cell carcinoma (mcdRCC) are unavailable. We addressed this knowledge gap and tested rates of treatment and associated mortality in patients with mcdRCC.PATIENTS AND METHODS: Within Surveillance, Epidemiology, and End Results database (2004-2018), we identified 155 mcdRCC patients. Kaplan-Meier plots and Cox proportional hazards regression models tested the effect of treatment (cytoreductive nephrectomy [CN] alone vs. systemic therapy [ST] alone vs. combination of both CN + ST) on overall mortality (OM).RESULTS: In the overall cohort (n = 155), 57 patients (37%) were treated with combination of both CN + ST, 46 (30%) underwent CN alone, 28 (18%) received ST alone, and 24 (15%) had none/unknown treatment. According to age categories (≤ 59 vs. 60-69 vs. ≥ 70 years), rates of combination of both CN + ST were 45% vs. 45% vs. 14%, respectively. CN alone was the most frequent type of treatment in patients aged ≥ 70 (50%). Median overall survival was 4.0 months for CN alone vs. 5.5 months for ST alone vs. 9.0 months for combination of both CN+ST. In multivariable Cox regression models, where CN alone was the referent, the use of ST alone and combination of both CN + ST were respectively associated with a HR of 0.74 (P = .3) and 0.43 (P < .001), after adjustment for all covariates.CONCLUSIONS: In mcdRCC patients, concomitant use of CN and ST results in lowest mortality, followed by ST alone, and CN alone. In consequence combination of both CN + ST should be recommended whenever applicable.

U2 - 10.1016/j.clgc.2022.08.010

DO - 10.1016/j.clgc.2022.08.010

M3 - SCORING: Journal article

C2 - 36117092

VL - 21

SP - 295

EP - 300

JO - CLIN GENITOURIN CANC

JF - CLIN GENITOURIN CANC

SN - 1558-7673

IS - 2

ER -